427 related articles for article (PubMed ID: 30072391)
1. Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants.
Patel SA; Longacre TA; Ladabaum U; Lebensohn A; Lin AY; Haraldsdottir S
Oncologist; 2018 Dec; 23(12):1395-1400. PubMed ID: 30072391
[TBL] [Abstract][Full Text] [Related]
2. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
Carethers JM; Stoffel EM
World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
[TBL] [Abstract][Full Text] [Related]
3. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
4. Methylation Tolerance-Based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome.
Bouvet D; Bodo S; Munier A; Guillerm E; Bertrand R; Colas C; Duval A; Coulet F; Muleris M
Gastroenterology; 2019 Aug; 157(2):421-431. PubMed ID: 30998989
[TBL] [Abstract][Full Text] [Related]
5. Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair-deficiency and Lynch syndrome.
Maletzki C; Huehns M; Bauer I; Ripperger T; Mork MM; Vilar E; Klöcking S; Zettl H; Prall F; Linnebacher M
Mol Carcinog; 2017 Jul; 56(7):1753-1764. PubMed ID: 28218421
[TBL] [Abstract][Full Text] [Related]
6. Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas.
Buckley AR; Ideker T; Carter H; Harismendy O; Schork NJ
Genome Med; 2018 Sep; 10(1):69. PubMed ID: 30217226
[TBL] [Abstract][Full Text] [Related]
7. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
[TBL] [Abstract][Full Text] [Related]
8. Mismatch Repair Screening of Gastrointestinal Cancers: The Impact on Lynch Syndrome Detection and Immunotherapy.
R OM; J W; T F; C M; A W; N S; Z K
J Gastrointest Cancer; 2023 Sep; 54(3):768-775. PubMed ID: 36018445
[TBL] [Abstract][Full Text] [Related]
9. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
[TBL] [Abstract][Full Text] [Related]
10. The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
Sorscher S
Oncologist; 2018 Nov; 23(11):1266-1268. PubMed ID: 29866945
[TBL] [Abstract][Full Text] [Related]
11. Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers.
Kang SY; Park CK; Chang DK; Kim JW; Son HJ; Cho YB; Yun SH; Kim HC; Kwon M; Kim KM
Int J Cancer; 2015 Apr; 136(7):1568-78. PubMed ID: 25110875
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
[TBL] [Abstract][Full Text] [Related]
15. Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma.
Shia J
Semin Diagn Pathol; 2015 Sep; 32(5):352-61. PubMed ID: 25716099
[TBL] [Abstract][Full Text] [Related]
16. Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.
Houlleberghs H; Dekker M; Lantermans H; Kleinendorst R; Dubbink HJ; Hofstra RM; Verhoef S; Te Riele H
Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4128-33. PubMed ID: 26951660
[TBL] [Abstract][Full Text] [Related]
17. Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors.
Woerner SM; Tosti E; Yuan YP; Kloor M; Bork P; Edelmann W; Gebert J
Mol Carcinog; 2015 Nov; 54(11):1376-86. PubMed ID: 25213383
[TBL] [Abstract][Full Text] [Related]
18. DNA mismatch repair in cancer.
Baretti M; Le DT
Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262
[TBL] [Abstract][Full Text] [Related]
19. Approaches to diagnose DNA mismatch repair gene defects in cancer.
Peña-Diaz J; Rasmussen LJ
DNA Repair (Amst); 2016 Feb; 38():147-154. PubMed ID: 26708048
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
